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Duration of Clopidogrel Therapy with Drug-Eluting Stents
To the Editor: In their article about the dura-
tion of dual antiplatelet therapy after implanta-
tion of drug-eluting stents, Park and colleagues 
(April 15 issue)1 report that the use of extended 
dual antiplatelet therapy in patients who had re-
ceived drug-eluting stents was not significantly 
more effective than aspirin monotherapy in re-
ducing the rate of myocardial infarction or death 
from cardiac causes. Yet the rate of a composite 
of myocardial infarction, stroke, or death from 
any cause was nearly significantly higher in pa-
tients receiving extended dual antiplatelet therapy 
than in those receiving aspirin alone. These re-
sults are unpredictable and thus are difficult to 
interpret, although the authors commented that 
the results seem most likely to be due to chance. 
Stent length is a known predictor of stent throm-
bosis and thus myocardial infarction after treat-
ment with a drug-eluting stent.2 Did the trend 
toward the use of longer stents in patients receiv-
ing extended dual antiplatelet therapy as compared 
with patients receiving aspirin (P = 0.07) affect 
the higher incidence of myocardial infarction, 
stroke, or death from any cause? Furthermore, 
several medications (cilostazol,3 metformin,4 pio-
glitazone,5 and angiotensin-receptor blockers) 
have been reported to decrease the incidence of 
death or myocardial infarction. Is it possible that 
differences in the use of these medications affect 
the results?
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To the Editor: On reading the article by Park 
and colleagues comparing aspirin alone and dual 
therapy with clopidrogel and aspirin to decrease 
adverse events 12 months after cardiac stenting, 
we are surprised that, given the failure to show a 
benefit, the obvious trend toward harm with dual 
therapy was not analyzed further, since the out-
come of myocardial infarction, stroke, or death 
from cardiac causes showed a trend toward a 
worse outcome with dual therapy. The inclusion of 
major bleeding events to this composite outcome 
this week’s letters
488 Duration of Clopidogrel Therapy with Drug-
Eluting Stents
491 Physician Cost Profiling
493 Outpatient Management of Severe COPD
495 What’s Keeping Us So Busy in Primary Care?
496 PLA2R Autoantibodies and Recurrent 
 Membranous Nephropathy after Transplantation
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on February 26, 2013. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
correspondence
n engl j med 363;5 nejm.org july 29, 2010 489
would have resulted in the difference between 
the two groups reaching significance (P = 0.03).
This is not dissimilar to the findings for po-
tent anticoagulants by Sharrock and colleagues,1 
who examined anticoagulation strategies to re-
duce mortality from any cause following joint 
arthroplasty. The use of potent anticoagulants 
not only failed to reduce the rate of thromboem-
bolic events but increased the rate of death from 
any cause.
We conclude that newer anticoagulants must 
undergo more stringent evaluation as evidence 
emerges that they not only fail to achieve their 
primary purpose but also may increase the risk 
of complications.
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To the Editor: Park and colleagues did not find 
a beneficial effect when dual antiplatelet therapy 
was continued beyond 12 months in patients with 
drug-eluting stents. Although they describe sev-
eral limitations of their study, an important lim-
itation is missing, especially if we consider that 
the participants were Korean. A recent study 
showed that up to 51% of the Korean population 
(as compared with 24.5% of whites) have specific 
alleles on CYP2C19 that are associated with poor 
metabolism of some drugs.1 Indeed, several stud-
ies have shown increased resistance to clopido-
grel and worse outcomes in patients with poor 
metabolism of clopidogrel prescribed for acute 
coronary syndromes2 and after elective stent pro-
cedures.3
In the study described by Park and colleagues, 
no information is given on the distribution of 
the CYP2C19 polymorphism among the partici-
pants. Therefore, it is unclear whether the nega-
tive results are due to clopidogrel resistance in 
the studied population or to lack of efficacy be-
yond 12 months of treatment. We believe that 
genetic variation is an additional reason to be 
conservative with the extrapolation of these find-
ings to other parts of the world.
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To the Editor: The article by Park and col-
leagues is an important contribution to further 
defining the optimal antiplatelet therapy in pa-
tients receiving drug-eluting stents. Currently 
available data, on which present guidelines are 
based, were collected mostly in North America 
and Western Europe.1 The article by Park and 
colleagues adds important information about a 
large Asian population.
Marked lifestyle differences and possible ge-
netic heterogeneity translate into a relatively low 
prevalence and incidence of coronary artery dis-
ease in relation to cerebrovascular disease in 
Asia, as compared with Western countries.2 This 
may be the reason why the study by Park and 
coworkers was not sufficiently powered with 
regard to the primary and secondary end points. 
Substantial evidence indicates that Asian patients 
tend to require lower doses of anticoagulation 
therapy — including warfarin,3 tissue plasmino-
gen activators,4 and even antiplatelet treatment2 
—  than do Western patients.
These differences show that guidelines devel-
oped in Western countries cannot easily be trans-
ferred globally. The reverse restriction also ap-
plies: the transfer of the conclusions drawn by Park 
and colleagues in Asian patients to non-Asian 
populations necessitates considerable caution.
Christoph Knosalla, M.D., Ph.D. 
Michael Dandel, M.D., Ph.D. 
Roland Hetzer, M.D., Ph.D.
Deutsches Herzzentrum Berlin 
Berlin, Germany 
knosalla@dhzb.de
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on February 26, 2013. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 363;5 nejm.org july 29, 2010490
No potential conflict of interest relevant to this letter was re-
ported.
King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused 1. 
update of the ACC/AHA/SCAI 2005 Guideline Update for Percu-
taneous Coronary Intervention: a report of the American College 
of Cardiology/American Heart Association Task Force on Prac-
tice Guidelines: 2007 Writing Group to Review New Evidence 
and Update the ACC/AHA/SCAI 2005 Guideline Update for Per-
cutaneous Coronary Intervention, writing on behalf of the 2005 
Writing Committee. Circulation 2008;117:261-95.
Goto S, Toda E. Antiplatelet therapy after coronary interven-2. 
tion in Asia and Japan: the Asian perspective of antiplatelet in-
tervention. Hamostaseologie 2009;29:321-5.
Cheng TO. Maintenance doses of warfarin in Chinese pa-3. 
tients. QJM 1996;89:557.
Ross AM, Gao R, Coyne KS, et al. A randomized trial con-4. 
firming the efficacy of reduced dose recombinant tissue plas-
minogen activator in a Chinese myocardial infarction popula-
tion and demonstrating superiority to usual dose urokinase: the 
TUCC trial. Am Heart J 2001;142:244-7.
The Authors Reply: Regarding the comments 
of Okura: Owing to lower-than-expected rates of 
outcomes, our study was underpowered to detect 
a clinically significant difference between the 
two groups. Although the confidence interval of 
the relative treatment effect was wide, the results 
rule out all but a modest benefit of continued 
dual antiplatelet therapy and raise the possibility 
that prolonged dual antiplatelet therapy would be 
harmful. Thus, we believe that our results could 
be clinically directive. Adjustment of significant 
covariates, including stent length, in a multivari-
able Cox regression model did not substantially 
alter the estimate of the relative risks of the out-
comes. Furthermore, the use of other cardioac-
tive medications at discharge and during follow-
up was well balanced between the two groups; 
therefore, it might not affect the results.
Regarding the comments of Memtsoudis and 
Sharrock: In our study, the rates of the two com-
posite outcomes (myocardial infarction or stroke 
or either death from any cause or death from 
cardiac causes) were not significantly greater with 
dual therapy than with aspirin monotherapy, but 
a trend prompting concern was noted. Due to 
low numbers of events and inherent limitations 
of secondary-outcomes analysis, these findings 
should be interpreted with caution, and it does 
not appear that the type of treatment adequately 
explains the observed difference in the rates of 
serious composite outcomes. So the related find-
ings are due to chance, or — it could be specu-
lated in clinically stable patients representing a 
crude proxy for patients with reduced basal 
platelet activity — a provocative, harmful effect 
of long-term clopidogrel use might exist.1
Regarding the comments of Rennings and 
colleagues: The considerable variation in respon-
siveness and resistance to clopidogrel suggests2 
that long-term clopidogrel use does not always 
ensure a consistent protective effect in recipients 
of drug-eluting stents. We also believe that mark-
edly different gene variants among ethnic groups 
might affect the results of clopidogrel use world-
wide.3 Therefore, further studies of individual-
ized antiplatelet therapy that involve genotyping 
should be conducted, for purposes of optimal 
antiplatelet treatment.4
Regarding the comments of Knosalla and 
colleagues: We acknowledge that relatively lower 
rates of clinical outcomes in our study, as com-
pared with rates in Western studies, might be 
partly due to differences in the populations of 
patients, lesion characteristics, interventional 
practices, or ethnic or genetic diversity,5 poten-
tially limiting the reproducibility of our results 
in other settings. However, an unexpected and 
detrimental effect of long-term clopidogrel use 
was also seen in a low-risk group of Western 
subjects, and our findings should therefore be 
reconfirmed or refuted through large clinical 
trials conducted in other ethnic groups.
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